DBCG HYPO 试验全乳放疗剂量约束的质量评估
该研究基于 DBCG HYPO 随机试验中 1854 例全乳放疗患者的计划质量评估,前瞻性报告剂量学参数并与预设约束比较。结果显示心脏和肺约束依从性>99%,但 CTV 覆盖率偏差最大;据此提出全乳放疗危及器官剂量和高剂量体积的新约束建议。
要点
- 心脏和肺剂量约束依从性>99%,CTV 覆盖率偏差最大。
- 40 Gy 与 50 Gy 计划多数剂量学参数无显著差异。
- 提出全乳放疗危及器官剂量和高剂量体积的新约束建议。
核心结论
- DBCG HYPO 试验治疗计划对方案剂量约束依从性高,建议全乳放疗采用新的危及器官剂量和乳腺高剂量体积约束。
研究设计与样本
- 2009 至 2014 年随机对照试验,1882 例患者随机接受 50 Gy/25 次或 40 Gy/15 次全乳放疗,前瞻性报告剂量学参数并与预设约束比较。
主要发现
- 共 1854 例来自 3 国 8 个放疗中心的患者接受治疗,40 Gy 与 50 Gy 计划除 CTVp_breast 热点体积(V107%-V110%)外无统计学显著差异。
- 40 Gy 计划中,CTVp_breast>600 mL 者 90% 和 ≤600 mL 者 95% 的 V105%-V107%<2%。
- 50 Gy 计划中,95% 计划 CTVp_breast 绝对热点体积(V107%-V110%)在 ≤600 mL 和 >600 mL 者分别为<0.5 mL 和<1.7 mL。
- 心脏和肺约束依从性均>99%,CTVp_breast V95% 偏差最大;右侧患者 95% 的 V95%>94.3%,左侧接受与未接受呼吸门控者分别为 93.2% 和 88.8%。
关键数值与推荐
- 40 Gy 计划新增 V105%-V107% 约束:CTVp_breast>600 mL 时 90% 患者<2%,≤600 mL 时 95% 患者<2%。
- 50 Gy 计划 CTVp_breast 绝对热点体积(V107%-V110%):≤600 mL 时 95% 患者<0.5 mL,>600 mL 时 95% 患者<1.7 mL。
- 心脏和肺约束依从性>99%,CTVp_breast V95% 在右侧 95% 患者>94.3%,左侧呼吸门控者 93.2%、未门控者 88.8%。
临床怎么用
- 全乳放疗计划设计可参考本试验提出的心脏、肺及乳腺高剂量体积约束。
- 左侧乳腺癌建议使用呼吸门控技术以改善 CTV 覆盖率。
- CTVp_breast 较大(>600 mL)时需关注热点体积控制。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Quality assessment of the treatment plans in the Danish Breast Cancer Group (DBCG) HYPO trial was carried out based on prospectively reported dosimetric parameters and evidence-based dose constraints for whole breast radiation therapy were derived. MATERIALS AND METHODS: From 2009 to 2014, 1882 patients (pts) were randomised between 50 Gy/25fractions (fr) versus 40 Gy/15fr. Doses to CTVp_breast (V95%, V107%-V110%, Dmax, and in addition for 40 Gy plans V105%-V107%), ipsilateral lung (V20Gy/V17Gy), heart (V20Gy/V17Gy, V40Gy/V35Gy), and left anterior descending coronary artery (LADCA) (Dmax) and use of respiratory gated technique were prospectively reported to the DBCG database. After end of accrual, these dosimetric parameters from all plans in the trial were compared to the pre-specified treatment constraints. RESULTS: In total, 1854 pts from eight radiation therapy (RT) centres in three countries were treated. No statistically significant differences were found between the results for 40 Gy and 50 Gy plans, except for CTVp_breast hot-spot volume (V107%-V110%). Of the 40 Gy pts, 90% with CTVp_breast > 600 mL and 95% with CTVp_breast ≤ 600 mL had a CTVp_breast hot-spot volume (V105%-V107%) <2%. In 95% of the 50 Gy plans, the CTVp_breast absolute hot-spot volume (V107%-V110%) was <0.5 mL and 1.7 mL for CTVp_breast ≤ 600 mL and > 600 mL, respectively. Compliance was >99% for both heart and lung constraints. Largest deviation from protocol constraints was found for the volume of CTVp_breast covered with 95% of the prescription dose or more (V95%). The CTV dose coverage (V95%) was >94.3% in 95% of the right-sided pts, whereas the figures for 95% of the left-sided pts treated with and without respiratory gating were 93.2% and 88.8%, respectively. CONCLUSION: A high degree of compliance with protocol dose constraints was found for treatment plans in the DBCG HYPO trial. New constraints for dose to organs at risk and high-dose volumes in the breast are suggested for breast-only RT planning.
引用
- Thomsen MS, Berg M, Zimmermann S, et al. Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial. Clin Transl Radiat Oncol. 2021. PMID: 33937532. doi:10.1016/j.ctro.2021.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。